9,480 Shares in Masimo Corporation $MASI Acquired by Dynamic Technology Lab Private Ltd

Dynamic Technology Lab Private Ltd acquired a new position in shares of Masimo Corporation (NASDAQ:MASI) during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm acquired 9,480 shares of the medical equipment provider’s stock, valued at approximately $1,233,000.

Other institutional investors have also recently added to or reduced their stakes in the company. Caitong International Asset Management Co. Ltd purchased a new stake in Masimo in the fourth quarter valued at $38,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its position in Masimo by 9.0% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 118,964 shares of the medical equipment provider’s stock valued at $15,472,000 after purchasing an additional 9,854 shares during the period. Wells Fargo & Company MN raised its position in Masimo by 8.2% in the fourth quarter. Wells Fargo & Company MN now owns 18,697 shares of the medical equipment provider’s stock valued at $2,432,000 after purchasing an additional 1,417 shares during the period. Federation des caisses Desjardins du Quebec raised its position in Masimo by 18.2% in the fourth quarter. Federation des caisses Desjardins du Quebec now owns 3,657 shares of the medical equipment provider’s stock valued at $476,000 after purchasing an additional 564 shares during the period. Finally, HRT Financial LP purchased a new stake in Masimo in the fourth quarter valued at $12,066,000. Hedge funds and other institutional investors own 85.96% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts have commented on MASI shares. Piper Sandler downgraded Masimo from an “overweight” rating to a “hold” rating and set a $180.00 target price on the stock. in a research report on Tuesday, February 17th. Stifel Nicolaus set a $180.00 target price on Masimo in a research report on Tuesday, February 17th. Weiss Ratings upgraded Masimo from a “sell (d-)” rating to a “hold (c-)” rating in a research report on Wednesday, May 6th. BTIG Research downgraded Masimo from a “buy” rating to a “neutral” rating in a research report on Wednesday, February 18th. Finally, Raymond James Financial downgraded Masimo from an “outperform” rating to a “market perform” rating in a research report on Friday, March 27th. Nine research analysts have rated the stock with a Hold rating, Based on data from MarketBeat.com, Masimo presently has a consensus rating of “Hold” and a consensus price target of $180.40.

Masimo Stock Performance

Shares of NASDAQ MASI opened at $179.95 on Friday. Masimo Corporation has a twelve month low of $125.94 and a twelve month high of $179.99. The company has a current ratio of 2.68, a quick ratio of 1.45 and a debt-to-equity ratio of 0.56. The stock has a fifty day simple moving average of $178.70 and a 200-day simple moving average of $160.55. The stock has a market capitalization of $9.42 billion, a PE ratio of -17.07, a PEG ratio of 1.82 and a beta of 1.11.

Masimo Company Profile

Masimo (NASDAQ: MASI) is a global medical technology company specializing in noninvasive monitoring solutions. The company’s flagship technology, Masimo SET® (Signal Extraction Technology), enhances the accuracy of pulse oximetry in challenging clinical conditions. Beyond pulse oximetry, Masimo’s portfolio extends to brain function monitoring, regional oximetry, and acoustic respiration rate monitoring, serving critical, acute, and ambulatory care settings.

In addition to its core monitoring technologies, Masimo offers a range of patient cables, sensors, and connectivity platforms designed to integrate with hospital information systems and remote monitoring applications.